EVENT PULSE: ASH 2009
Study Overview:
Event Pulse is a syndicated report series that evaluates the impact of market events on the treatment practices of physicians. These report series provide information on how changes such as new products, data, or guidelines fit into the treatment algorithm, impact current therapies and change market dynamics.
We are leveraging our multi-faceted healthcare market research platform to conduct an in-depth analysis of physician’s current treatment behaviors in multiple myeloma and non-Hodgkin’s lymphoma, and to predict how their treatment decisions will change in the future as a result of clinical findings presented at ASH 2009.
REASONS TO PURCHASE
|
By combining our primary research and longitudinal oncology datasets, we will help our clients answer these key business questions:
- Which clinical trial results presented at ASH 2009 will have the greatest impact on treatment practices for multiple myeloma and NHL?
- How will the initial results from MM-015 impact future multiple myeloma share levels for Revlimid and Velcade in the front-line and maintenance settings?
- Will the initial results from NHL-003 encourage further adoption of Revlimid for NHL?
- Do doctors intend to increase combination use of Rituxan+Treanda to treat NHL, based on findings from the StiL study?
- How are physicians reacting to new agents undergoing clinical trials for the treatment of NHL and multiple myeloma?
- What are the top drugs in each major disease classification of NHL and multiple myeloma, and how much share does each drug hold in those particular settings? (e.g., front-line, maintenance setting, pre/post-transplant for multiple myeloma; e.g., indolent/aggressive,follicular/large cell/mantle cell/marginal zone for NHL)
|
REPORT DETAILS
|
Methodology:
- Targeted Internet Survey of 75 hematologists/oncologists who attended ASH 2009
- 2 In-Depth Telephone Interviews of KOLs (Key Opinion Leaders) in Clinical Oncology
- Analysis of longitudinal data on 340+ NHL patients and 8800+ multiple myeloma patients from a nationwide network of 800+ oncology clinics spanning 2003-2009
- Analysis of daily treatment decisions from a panel of 425 oncologists and hematologists spanning 2005-2009 – includes off-label drug use, and breakdown of drug applications by line of therapy and by disease status
Key Clinical Trials Under Focus:
- MM-015 (Abstract 613) - Phase III trial in Newly Diagnosed Multiple Myeloma Patients to determine the efficacy and safety of Revlimid (lenalidomide) in combination with Melphalan and Prednisone (MPR)
- NHL-003 (Abstract 1676) – Phase II trial reviewing Revlimid (lenalidomide) as monotherapy in Relapsed /Refractory Aggressive Non-Hodgkin’s Lymphoma
- StiL Study (Abstract 405) – Phase III NHL trial evaluating Treanda (bendamustine) + Rituxan (rituximab) versus CHOP plus Rituxan for First-Line Treatment of Advanced Follicular, Indolent, and Mantle Cell Lymphomas
Report Contents - Multiple Myeloma:
Current Treatment Practices
Unaided Response to ASH 2009 Data
Response to MM-015
Response to Novel Agents
Report Contents - Non-Hodgkin´s Lymphoma
Current Treatment Practices
Unaided Response to ASH 2009 Data
Response to NHL-003
Response to StiL Study (Rituxan+Treanda)
Response to Novel Agents
Drugs/Companies That Will be Affected by These Findings:
Marketed:
- Revlimid and Thalomid (CELG)
- Velcade (Takeda, MLNM, JNJ)
- Treanda (CEPH)
- Rituxan (DNA, RHHBY)
- Zevalin (SPPI)
- Mozobil (GENZ)
- Doxil (OrthoBiotech, JNJ)
- Bexxar (GSK)
- Gemzar (LLY)
Pipeline:
- carfilzomib (ONXX)
- clofarabine (GENZ)
- ofatumumab (Genmab, GSK)
For more information, please contact us by clicking HERE
|
